ALZN
Alzamend Neuro, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.31
+0.38%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-156.8%
Return on equity
-106.5%
Return on assets
-156.7%
Return on invested capital
0.00x
Asset turnover
-$6.8M
Cash from operations
$1.57
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jul 1, 2026